Indian Diabetes Diagnosis and Treatment Market
Indian Diabetes Diagnosis and Therapeutics Market Size, Share & Trends Analysis Report by Disease Type (Type 1 Diabetes, Type 2 Diabetes, and Gestational), by Drug Type (Oral anti-diabetic Drugs, Non-Insulin Injectable drugs, and Combination Drugs), and by Device Type (Blood Glucose Monitoring Devices, Blood Glucose Strips, Insulin devices, and Others) Forecast Period (2022-2028) Update Available - Forecast 2024-2030
The Indian diabetes diagnosis and therapeutics market is anticipated to grow at a CAGR of 7% during the forecast period. India is a significant market for diabetes diagnosis and treatment. Indian diabetes diagnosis and therapeutics market are influenced by the increasing prevalence of diabetes in India. According to the International Diabetes Federation (IDF), in 2020, 463 million people have diabetes globally and 88 million people in the Southeast Asia region. Additionally, out of these 88 million people, 77 million belong to India. Furthermore, as per the same source, the prevalence of diabetes in the population in India is 8.9%. With the increase in the Indian diabetic population, government institutions and pharmaceutical companies are concentrating majorly on developing innovative products India is the second most populated nation across the globe, both in terms of total and diabetic population, after China. It is expected that India will go past China by 2030 both in terms of population and diabetic population as per WHO.
Impact of COVID-19 Pandemic on Indian Diabetes Diagnosis and Therapeutics Market
The COVID-19 pandemic had a negative impact on the Indian diabetes diagnosis and therapeutics market. During COVID-19, as of May 2020, 212 countries had been impacted by the pandemic, and the governments of these countries had ordered nationwide lockdowns due to which many hospitals were converted into COVID-19 centers due to which diabetics faced delays in treatment. Furthermore, the entire healthcare sector’s focus shifted toward COVID-19. Thus, COVID-19 adversely affected the growth of the diabetes therapeutics market.
Segmental Outlook
The Indian diabetes diagnosis and therapeutics market is segmented based on disease type, drug type, and device type. Based on the disease type, the market is further classified into Type 1 Diabetes, Type 2 Diabetes, and gestational. Based on drug type, the market is further segmented into oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs. Based on the device type, the market is further segregated into blood glucose monitoring devices, blood glucose strips, insulin devices, and others (lancets).
Indian Diabetes Diagnosis and Therapeutics Market Share by Disease Type, 2021 (%)
Type 2 Diabetes Segment is Expected to Grow at a Significant CAGR in the Indian Diabetes Diagnosis and Therapeutics Market
Based on the disease type, the type 2 diabetes segment is expected to grow at a significant rate during the forecast period. The growth of the segment is attributed to the increasing prevalence of Type 2 diabetes. According to WHO, Type 2 diabetes is the most prevalent form of diabetes making up to 90% of the total cases. Type 2 diabetes is caused due to obesity, a sedentary lifestyle, poor eating habits, and other lifestyle issues. Type 2 diabetes generally occurs in adolescence and is incurable. It is characterized by insulin resistance and the relative shortage of insulin levels which can be diagnosed through innovative medical equipment. The diagnosis of Type 2 diabetes majorly occurs after the age of 40 years; however, there are also chances of it occurring in the early ages, especially in populations with high diabetes prevalence. Type 2 diabetes can remain undetected for many years and the diagnosis is often made from associated complications or incidentally through abnormal blood or urine glucose test.
Market Players Outlook
The major companies serving the Indian diabetes diagnosis and therapeutics market include Elli Lilly and Co., Merck & Co., Inc., Novartis International AG, Pfizer Inc., and Glenmark Pharmaceuticals Ltd., among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, geographical expansion, and collaborations to stay competitive in the market. For instance, in December 2019, Roche's received the CE approval for the Accu-Chek SugarView blood glucose monitoring app. Accu-Chek SugarView app enables the availability of relevant therapy information and support in the everyday life of diabetes patients.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the Indian diabetes diagnosis and therapeutics market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1.Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Impact of COVID-19 on the Indian Diabetes Diagnosis and Therapeutics Market
- Recovery Scenario of Indian Diabetes Diagnosis and Therapeutics Market
1.1.Research Methods and Tools
1.2.Market Breakdown
1.2.1.By Segments
2. Market Overview and Insights
2.1.Scope of the Report
2.2.Analyst Insight & Current Market Trends
2.2.1.Key Findings
2.2.2.Recommendations
2.2.3.Conclusion
3.Competitive Landscape
3.1.Key Company Analysis
3.2.Eli Lilly and Co.
3.2.1.Overview
3.2.2.Financial Analysis
3.2.3.SWOT Analysis
3.2.4.Recent Developments
3.3.Merck & Co., Inc.
3.3.1.Overview
3.3.2.Financial Analysis
3.3.3.SWOT Analysis
3.3.4.Recent Developments
3.4.Novartis International AG
3.4.1.Overview
3.4.2.Financial Analysis
3.4.3.SWOT Analysis
3.4.4.Recent Developments
3.5.Pfizer Inc.
3.5.1.Overview
3.5.2.Financial Analysis
3.5.3.SWOT Analysis
3.5.4.Recent Developments
3.6.Glenmark Pharmaceuticals Ltd.
3.6.1.Overview
3.6.2.Financial Analysis
3.6.3.SWOT Analysis
3.6.4.Recent Developments
3.7.Key Strategy Analysis
3.8.Impact of COVID-19 on Key Players
4.Market Segmentation
4.1.Indian Diabetes Diagnosis and Therapeutics Market by Disease Type
4.1.1.Type 1 Diabetes
4.1.2.Type 2 Diabetes
4.1.3.Gestational
4.2.Indian Diabetes Diagnosis and Therapeutics Market by Drug Type
4.2.1.Oral anti-diabetic Drugs
4.2.2.Non-Insulin Injectable drugs
4.2.3.Combination Drugs
4.3.Indian Diabetes Diagnosis and Therapeutics Market by Device Type
4.3.1.Blood Glucose Monitoring Devices
4.3.2.Blood Glucose Strips
4.3.3.Insulin devices
4.3.4.Others (Lancets)
5.Company Profiles
5.1.AstraZeneca Plc
5.2.Eli Lilly and Co.
5.3.GlaxoSmithKline plc
5.4.Glenmark Pharmaceuticals Ltd.
5.5.Lupin Pharmaceuticals, Inc.
5.6.Merck & Co., Inc.
5.7.Micro Labs Ltd.
5.8.Novartis International AG
5.9.Novo Nordisk A/S
5.10.Pfizer Inc.
5.11.Sanofi Aventis
5.12.Sun Pharmaceutical Industries Ltd.
5.13.USV Pvt. Ltd.
1.INDIAN DIABETES DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2021-2028 ($ MILLION)
2.INDIAN DIABETES DIAGNOSIS AND THERAPEUTICS FOR TYPE 1 DIABETES MARKET RESEARCH AND ANALYSIS, 2021-2028 ($ MILLION)
3.INDIAN DIABETES DIAGNOSIS AND THERAPEUTICS FOR TYPE 2 DIABETES MARKET RESEARCH AND ANALYSIS, 2021-2028 ($ MILLION)
4.INDIAN DIABETES DIAGNOSIS AND THERAPEUTICS FOR GESTATIONAL MARKET RESEARCH AND ANALYSIS, 2021-2028 ($ MILLION)
5.INDIAN DIABETES DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
6.INDIAN DIABETES DIAGNOSIS AND THERAPEUTICS BY ORAL ANTI-DIABETIC DRUGS MARKET RESEARCH AND ANALYSIS, 2021-2028 ($ MILLION)
7.INDIAN DIABETES DIAGNOSIS AND THERAPEUTICS BY NON-INSULIN INJECTABLE DRUGS MARKET RESEARCH AND ANALYSIS, 2021-2028 ($ MILLION)
8.INDIAN DIABETES DIAGNOSIS AND THERAPEUTICS BY COMBINATION DRUGS MARKET RESEARCH AND ANALYSIS, 2021-2028 ($ MILLION)
9.INDIAN DIABETES DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DEVICE TYPE, 2021-2028 ($ MILLION)
10.INDIAN DIABETES DIAGNOSIS AND THERAPEUTICS BY BLOOD GLUCOSE MONITORING DEVICES MARKET RESEARCH AND ANALYSIS, 2021-2028 ($ MILLION)
11.INDIAN DIABETES DIAGNOSIS AND THERAPEUTICS BY BLOOD GLUCOSE STRIPS MARKET RESEARCH AND ANALYSIS, 2021-2028 ($ MILLION)
12.INDIAN DIABETES DIAGNOSIS AND THERAPEUTICS BY INSULIN DEVICES MARKET RESEARCH AND ANALYSIS, 2021-2028 ($ MILLION)
13.INDIAN DIABETES DIAGNOSIS AND THERAPEUTICS BY OTHERS (LANCETS) MARKET RESEARCH AND ANALYSIS, 2021-2028 ($ MILLION)
1.IMPACT OF COVID-19 ON INDIAN DIABETES DIAGNOSIS AND THERAPEUTICS MARKET, 2021-2028 ($ MILLION)
2.IMPACT OF COVID-19 ON INDIAN DIABETES DIAGNOSIS AND THERAPEUTICS MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3.RECOVERY OF INDIAN DIABETES DIAGNOSIS AND THERAPEUTICS MARKET, 2022-2028 (%)
4.INDIAN DIABETES DIAGNOSIS AND THERAPEUTICS MARKET SHARE BY DISEASE TYPE, 2021 VS 2028 (%)
5.INDIAN DIABETES DIAGNOSIS AND THERAPEUTICS FOR TYPE 1 DIABETES MARKET SHARE, 2021 VS 2028 (%)
6.INDIAN DIABETES DIAGNOSIS AND THERAPEUTICS FOR TYPE 2 DIABETES MARKET SHARE, 2021 VS 2028 (%)
7.INDIAN DIABETES DIAGNOSIS AND THERAPEUTICS FOR GESTATIONAL MARKET SHARE, 2021 VS 2028 (%)
8.INDIAN DIABETES DIAGNOSIS AND THERAPEUTICS MARKET SHARE BY DRUG TYPE, 2021 VS 2028 (%)
9.INDIAN DIABETES DIAGNOSIS AND THERAPEUTICS BY ORAL-ANTI DIABETIC DRUGS MARKET SHARE, 2021 VS 2028 (%)
10.INDIAN DIABETES DIAGNOSIS AND THERAPEUTICS BY NON-INSULIN INJECTABLE DRUGS MARKET SHARE, 2021 VS 2028 (%)
11.INDIAN DIABETES DIAGNOSIS AND THERAPEUTICS BY COMBINATION DRUGS MARKET SHARE, 2021 VS 2028 (%)
12.INDIAN DIABETES DIAGNOSIS AND THERAPEUTICS MARKET SHARE BY DEVICE TYPE, 2021 VS 2028 (%)
13.INDIAN DIABETES DIAGNOSIS AND THERAPEUTICS BY BLOOD GLUCOSE MONITORING DEVICES MARKET SHARE, 2021 VS 2028 (%)
14.INDIAN DIABETES DIAGNOSIS AND THERAPEUTICS BY BLOOD GLUCOSE STRIPS MARKET SHARE, 2021 VS 2028 (%)
15.INDIAN DIABETES DIAGNOSIS AND THERAPEUTICS BY INSULIN DEVICES MARKET SHARE, 2021 VS 2028 (%)
16. INDIAN DIABETES DIAGNOSIS AND THERAPEUTICS BY OTHERS (LANCETS) MARKET SHARE, 2021 VS 2028 (%)
